Nesen viens no liel\u0101kajiem farmaceitisko produktu ra\u017eot\u0101jiem Baltij\u0101 Grindeks n\u0101ca klaj\u0101 ar pazi\u0146ojumu, ka sav\u0101 60. jubilejas gad\u0101 ieg\u0101d\u0101jies patenta pieteikumu, lai att\u012bst\u012btu medikamentus HIV \u0101rstniec\u012bb\u0101. \u0160is nav vien\u012bgais a\/s Grindeks pan\u0101kums – zin\u0101m\u0101kie jau ir pa\u0161u rad\u012btie Mildron\u0101ts\u00ae<\/small>\u00a0un Ftoraf\u016brs. Uz\u0146\u0113mumam ir p\u0101rst\u0101vniec\u012bbas devi\u0146\u0101s valst\u012bs, un tas eksport\u0113 medikamentus uz 37 valst\u012bm.<\/p>\n\n\n\n
Grindeks uz\u0146\u0113muma att\u012bst\u012bb\u0101 no 2006. l\u012bdz 2009. gadam pl\u0101no ieguld\u012bt 34,42 miljonus latu. Uz\u0146\u0113mums jau gatavo projektu dokument\u0101ciju Eiropas Savien\u012bbas l\u012bdzfinans\u0113juma sa\u0146em\u0161anai vair\u0101kos jaunos virzienos, piem\u0113ram, jaunu produktu un tehnolo\u0123iju p\u0113tniec\u012bb\u0101, k\u0101 ar\u012b jaunu z\u0101\u013cu izstr\u0101d\u0113.<\/p>\n\n\n\n
\u00abKatru gadu vair\u0101k nek\u0101 10 miljoni cilv\u0113ku vis\u0101 pasaul\u0113 izmanto m\u016bsu rad\u012bt\u0101s z\u0101les vesel\u012bbas nostiprin\u0101\u0161anai vai atg\u016b\u0161anai. Grindeks produktu kl\u0101st\u0101 ir vair\u0101k nek\u0101 100 kvalitat\u012bvu, efekt\u012bvu un dro\u0161u medikamentu \u2013 gan sirds un asinsvadu z\u0101les, psihotrop\u0101s z\u0101les, pretv\u0113\u017ea z\u0101les, gastroenterolo\u0123isk\u0101s z\u0101les, prets\u0101pju un pretdrud\u017ea z\u0101les, gan ar\u012b dabas produkti. M\u0113s akt\u012bvi str\u0101d\u0101jam pie starptautiskas noz\u012bmes Grindeks ori\u0123in\u0101lproduktu kl\u012bnisko p\u0113t\u012bjumu programmas realiz\u0113\u0161anas, kas n\u0101kotn\u0113 dos iesp\u0113ju Grindeks ori\u0123in\u0101lproduktus re\u0123istr\u0113t daudz\u0101s pasaules valst\u012bs,\u00bb teikts uz\u0146\u0113muma m\u0101jaslap\u0101. K\u0101 tas viss notiek?<\/p>\n\n\n\n
Grindeks att\u012bst\u0101s Ir vair\u0101ki veidi, k\u0101 Grindek\u0101 <\/em>top jauni medikamenti.\u00abViens no tiem \u2013 no jau eso\u0161ajiem gatavo jaunas kompoz\u012bcijas un att\u012bsta t\u0101l\u0101k ar\u012b t\u0101 d\u0113v\u0113tos \u00abgeneric\u00bb medikamentus, otrs \u2013 piln\u012bgi jauni produkti, kurus nosaukt nevaru, kuri ir att\u012bst\u012bb\u0101 un desmit gadu laik\u0101 b\u016bs jaunas z\u0101les,\u00bb teic K. Veisa.<\/p>\n\n\n\n Z\u0101\u013cu ra\u017eo\u0161an\u0101 desmit gadi ir \u012bss laiks \u2013 tikai tad medikaments tiek re\u0123istr\u0113ts, pirms tam ir veikta ar\u012b izp\u0113te ar dz\u012bvniekiem un cilv\u0113kiem. Gadu vai divus \u00abpa\u0146em\u00bb re\u0123istr\u0101cija. Toties p\u0113c ori\u0123in\u0101l\u0101 medikamenta patent\u0113\u0161anas uz\u0146\u0113mumam apm\u0113ram 20 gadu vien\u012bgajam ir t\u0101 ra\u017eo\u0161anas ties\u012bbas. \u00abTas ir pluss katrai komp\u0101nijai,\u00bb jaunu medikamentu izstr\u0101des noz\u012bm\u012bbu pamato K. Veisa. V\u0113l\u0101k, kad patenta termi\u0146\u0161 beidzas, \u0161o medikamentu, t\u0101 d\u0113v\u0113to \u00abgeneric\u00bb, p\u0113c jau aprob\u0113t\u0101m metod\u0113m \u013cauts ra\u017eot ar\u012b citiem.<\/p>\n\n\n\n Nosaukumam ir noz\u012bme!<\/strong><\/p>\n\n\n\n \u0160\u0137ietami niec\u012bg\u0101s tabletes vai kapsulas ce\u013c\u0161 l\u012bdz pacientam neb\u016bt nav \u012bss un vienk\u0101r\u0161s. Ar\u012b \u00abgeneric\u00bb medikamentiem, kuriem beidzas patenta termi\u0146\u0161, j\u0101pag\u016bst iedot skan\u012bgu un pirc\u0113jiem pie\u0146emamu nosaukumu, lai z\u0101les var\u0113tu k\u013c\u016bt atpaz\u012bstamas. Piem\u0113ram, zopiklonu Grindeks pied\u0101v\u0101 k\u0101 somnolu. \u00abM\u0113s esam izdom\u0101ju\u0161i t\u0101du nosaukumu, kas cilv\u0113kiem pat\u012bk. Ja t\u0101d\u0101 veid\u0101 var \u00abieb\u012bd\u012bt\u00bb medikamentu tirg\u016b, ar\u012b tas m\u016bsu komp\u0101nijai ir k\u0101 jaunas z\u0101les,\u00bb saka K. Veisa. Piem\u0113ram, tailenols ir tas pats paracetamols, bet pasaul\u0113 vair\u0101k paz\u012bstams k\u0101 tailenols. \u00abFirmas t\u0101 dara, nosauc cit\u0101 v\u0101rd\u0101, un \u00abparast\u0101 z\u0101le\u00bb nav tik popul\u0101ra k\u0101 no jauna nosaukt\u0101. No t\u0101, k\u0101 protam medikamentu nosaukt, b\u016bs atkar\u012bgs, k\u0101 to var\u0113s \u00abielikt\u00bb tirg\u016b, vai cilv\u0113ki atcer\u0113sies, vai nosaukums b\u016bs saprotams. J\u0101b\u016bt pareiz\u0101 laik\u0101, ar pareizu produktu, pie pareiz\u0101s auditorijas un ar pareizo cenu,\u00bb uzskata K. Veisa.<\/p>\n\n\n\n Katrs uzlabojums prasa laiku Uz\u0146\u0113mum\u0101 ir jauno produktu komiteja, kur\u0101 zin\u0101tnieki pied\u0101v\u0101 idejas, un \u0161\u012b komiteja lemj, vai pasaul\u0113 \u0161\u012bs z\u0101les b\u016bs vajadz\u012bgas, vai t\u0101s \u00abstr\u0101d\u0101s\u00bb organism\u0101 un vai t\u0101p\u0113c to ra\u017eo\u0161ana j\u0101att\u012bsta. \u0160eit satiekas zin\u0101tnieki, \u0101rsti un saliek kop\u0101 visu pu\u0161u viedok\u013cus. Zin\u0101tnieks var dot daudz ideju, bet \u0101rsts \u2013 pateikt, k\u0101 medikaments iedarbosies. Ta\u010du tas viss v\u0113l j\u0101p\u0101rbauda. Piem\u0113ram, kardiologs p\u0113c pieredzes var pateikt, kas notiks ar konkr\u0113tu medikamentu kombin\u0101ciju pacienta organism\u0101. Komitejas s\u0113des notiek reizi ceturksn\u012b, uz t\u0101m ierodas ar\u012b profesori no \u0101rzem\u0113m, piem\u0113ram, no V\u0101cijas. \u00abIr lietas, ko m\u0113s att\u012bst\u0101m, ir ko atliekam \u2013 varb\u016bt k\u0101dreiz. Un ir t\u0101das, kur redzi \u2013 b\u016bs jauns medikaments! Tad uz\u0146\u0113muma padome lemj \u2013 j\u0101, str\u0101d\u0101sim \u0161aj\u0101 jom\u0101, naudu dosim,\u00bb saka K. Veisa. Jauno produktu att\u012bst\u012bbas jom\u0101 tiek veikta biomedic\u012bnisko prekl\u012bnisko p\u0113t\u012bjumu pl\u0101no\u0161ana un organiz\u0101cija. Ja ir veikta prekl\u012bnika, tas noz\u012bm\u0113, ka var pirkt patentu. Tad pie darba \u0137eras kl\u012bnisko p\u0113t\u012bjumu noda\u013ca, kas sadarbojas ar kol\u0113\u0123iem Somij\u0101, V\u0101cij\u0101, Krievij\u0101, pa\u0161m\u0101ju Organisk\u0101s sint\u0113zes instit\u016btu.<\/p>\n\n\n\n Vissare\u017e\u0123\u012bt\u0101k\u0101 un laikietilp\u012bg\u0101k\u0101 ir dokument\u0101cijas sagatavo\u0161ana un dro\u0161\u012bbas pras\u012bbu nodro\u0161in\u0101\u0161ana. Katrs posms jauna medikamenta izstr\u0101d\u0113 j\u0101izdara t\u0101, lai p\u0113c desmit gadiem t\u0101 re\u0123istr\u0101cija Eirop\u0101 notiktu un netiktu apstr\u012bd\u0113ta datu v\u0101k\u0161anas metodika. \u00abTas ir \u0161ausm\u012bgi liels darbs, lai sagatavotu p\u0113t\u012bjumu vien. Vienu tagad gatavojam, un pusgads pag\u0101jis,\u00bb koment\u0113 K. Veisa. Turkl\u0101t ar pavisam jauniem medikamentiem ir sare\u017e\u0123\u012bti kaut vai t\u0101p\u0113c, ka cilv\u0113ki \u0161o prepar\u0101tu nepaz\u012bst. \u00abTu esi pirmais. Ar\u012b \u0101rsti to v\u0113l nezina. Pat nav nek\u0101 l\u012bdz\u012bga, ar ko var\u0113tu sal\u012bdzin\u0101t! Viss j\u0101dara pa\u0161iem \u2013 j\u0101st\u0101sta \u0101rstiem, jo recep\u0161u z\u0101les nevar masu tirg\u016b reklam\u0113t. P\u0101rst\u0101vjiem, kuri st\u0101sta par medikamentu, j\u0101b\u016bt ar medic\u012bnas izgl\u012bt\u012bbu. Tas ir darbs ar cilv\u0113kiem. Tas nav k\u0101 kr\u0113slu reklam\u0113t,\u00bb noteic K. Veisa.<\/p>\n\n\n\n Sasniegumi<\/strong><\/p>\n\n\n\n Mildron\u0101ts\u00ae<\/small> \u2013 a\/s Grindeks vispiepras\u012bt\u0101kais ori\u0123in\u0101lprodukts, sirds un asinsvadu l\u012bdzek\u013cu grupas vado\u0161ais medikaments, kas ir sasniedzis iev\u0113rojamus p\u0101rdo\u0161anas apjomus Baltijas un NVS z\u0101\u013cu tirg\u016b. Tas ir tre\u0161ais visvair\u0101k pirktais medikaments Ukrain\u0101 un Baltkrievij\u0101.<\/p>\n\n\n\n Sava unik\u0101l\u0101 iedarb\u012bbas meh\u0101nisma d\u0113\u013c Mildron\u0101ts\u00ae<\/small>, atkar\u012bb\u0101 no ordin\u0113t\u0101s devas, tiek pla\u0161i lietots gan k\u0101 recep\u0161u medikaments da\u017e\u0101du sirds un asinsvadu slim\u012bbu \u0101rst\u0113\u0161an\u0101, gan darbasp\u0113ju paaugstin\u0101\u0161anai veseliem cilv\u0113kiem pie fizisk\u0101m un gar\u012bg\u0101m p\u0101rslodz\u0113m un atvese\u013co\u0161an\u0101s period\u0101.<\/p>\n\n\n\n Ftoraf\u016brs \u2013 a\/s Grindeks ori\u0123in\u0101lprepar\u0101ts, pretv\u0113\u017ea l\u012bdzek\u013cu grupas vado\u0161ais medikaments, pla\u0161i lietots \u0137\u012bmijterapeitiskais l\u012bdzeklis da\u017e\u0101du \u013caundab\u012bgu audz\u0113ju, \u012bpa\u0161i ku\u0146\u0123a, resn\u0101s un taisn\u0101s zarnas v\u0113\u017ea, ar\u012b kr\u016bts v\u0113\u017ea \u0101rst\u0113\u0161anai. Nesen viens no liel\u0101kajiem farmaceitisko produktu ra\u017eot\u0101jiem Baltij\u0101 Grindeks n\u0101ca klaj\u0101 ar pazi\u0146ojumu, ka sav\u0101 60. jubilejas gad\u0101 ieg\u0101d\u0101jies patenta pieteikumu, lai att\u012bst\u012btu medikamentus HIV…<\/p>\n","protected":false},"author":3,"featured_media":6601,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[2],"tags":[],"class_list":["post-257","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-jaunums"],"acf":[],"_links":{"self":[{"href":"https:\/\/grindeks.com\/lv\/wp-json\/wp\/v2\/posts\/257","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/grindeks.com\/lv\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/grindeks.com\/lv\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/grindeks.com\/lv\/wp-json\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/grindeks.com\/lv\/wp-json\/wp\/v2\/comments?post=257"}],"version-history":[{"count":0,"href":"https:\/\/grindeks.com\/lv\/wp-json\/wp\/v2\/posts\/257\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/grindeks.com\/lv\/wp-json\/wp\/v2\/media\/6601"}],"wp:attachment":[{"href":"https:\/\/grindeks.com\/lv\/wp-json\/wp\/v2\/media?parent=257"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/grindeks.com\/lv\/wp-json\/wp\/v2\/categories?post=257"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/grindeks.com\/lv\/wp-json\/wp\/v2\/tags?post=257"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}
<\/strong>
\u00ab\u0160obr\u012bd sadarb\u012bb\u0101 ar zin\u0101tniekiem izstr\u0101d\u0101jam jaunas z\u0101les, kuras var\u0113tu ien\u0101kt tirg\u016b p\u0113c pieciem l\u012bdz desmit gadiem,\u00bb saka uz\u0146\u0113muma biznesa att\u012bst\u012bbas direktore Kintija Veisa. Sadarb\u012bba liel\u0101koties notiek ar Latvijas Organisk\u0101s sint\u0113zes instit\u016bta zin\u0101tniekiem un balst\u0101s uz vi\u0146u izstr\u0101d\u0101taj\u0101m prepar\u0101tu sint\u0113zes metod\u0113m. Starp citu, PSRS laik\u0101 katrs ceturtais jaunais medic\u012bniskais prepar\u0101ts tika rad\u012bts Latvij\u0101 un paredz\u0113ts visu 15 republiku tirgum. Ik gadu Grindeks<\/em> iegulda l\u012bdzek\u013cus p\u0113tniec\u012bb\u0101 un att\u012bst\u012bb\u0101, kas galvenok\u0101rt orient\u0113ta uz kardiovaskul\u0101ro, neirolo\u0123isko, pretv\u0113\u017ea un v\u012brusprepar\u0101tu att\u012bst\u012bbu. P\u0113tnieciskajiem projektiem vid\u0113ji gad\u0101 tiek atv\u0113l\u0113ti 8 \u2013 10 procenti no neto apgroz\u012bjuma. Gada laik\u0101 tiek realiz\u0113ti vid\u0113ji \u010detri l\u012bdz pieci p\u0113tniec\u012bbas projekti. Grindeks ir noz\u012bm\u012bgu patentu tur\u0113t\u0101js da\u017e\u0101d\u0101s pasaules valst\u012bs un gatavojas pieteikt virkni jaunu patentu. 2005. gad\u0101 uzs\u0101kts projekt\u0113t jaunu gatavo z\u0101\u013cu ra\u017eotni, kas Grindekam<\/em> \u013caus dubultot ra\u017eo\u0161anas jaudas un ra\u017eot vismaz 2 miljardus table\u0161u un kapsulu gad\u0101. Ar Eiropas Savien\u012bbas Att\u012bst\u012bbas fonda l\u012bdzfinans\u0113jumu p\u0113rn uzs\u0101kta ar\u012b jaunas akt\u012bvo farmaceitisko vielu anal\u012btisk\u0101s m\u0113rogo\u0161anas laboratorijas izveide. T\u0101 pa\u0101trin\u0101s jaunu akt\u012bvo substan\u010du ievie\u0161anu ra\u017eo\u0161an\u0101, tai skait\u0101 kl\u012bnisko p\u0113t\u012bjumu vajadz\u012bb\u0101m.<\/p>\n\n\n\n
<\/strong>
Pat it k\u0101 nenoz\u012bm\u012bgs tabletes vai kapsulas uzlabojums tiek uzskat\u012bts par papildu atkl\u0101jumu, pret kuru v\u0113rstas \u013coti stingras dro\u0161\u012bbas pras\u012bbas. \u00abIr firmas, kas \u00abgeneric\u00bb uzlabo ar papildu p\u0101rkl\u0101jumu, piem\u0113ram, lai netiktu boj\u0101ts ku\u0146\u0123is. Vai ar\u012b tabletei vid\u016b ieliek membr\u0101ni\u0146u, un z\u0101les ilg\u0101k izdal\u0101s. Faktiski tas ir jauns medikaments, kaut ar\u012b viela t\u0101 pati vec\u0101. Bet tas viss gandr\u012bz atbilst jaunas z\u0101les izstr\u0101dei, jo ir j\u0101p\u0113ta atkal no jauna. Tas ir v\u0113l viens virziens, ar ko nodarbojamies. Tas ir interesanti \u2013 dom\u0101t piecus, desmit gadus uz priek\u0161u. S\u0101kum\u0101 tu nezini, bet v\u0113l\u0101k jau j\u016bti \u2013 ah\u0101, farm\u0101cija iet uz to pusi!\u00bb st\u0101sta K. Veisa.<\/p>\n\n\n\n
Ftoraf\u016brs sintez\u0113ts 1964. gad\u0101 Latvijas Zin\u0101t\u0146u akad\u0113mijas Organisk\u0101s sint\u0113zes instit\u016bt\u0101, un t\u0101 rad\u012b\u0161ana uzskat\u0101ma par b\u016btisku etapu \u0137\u012bmijterapijas att\u012bst\u012bb\u0101.
Ftoraf\u016bra eksperiment\u0101lie un kl\u012bniskie p\u0113t\u012bjumi notiku\u0161i PSRS, Jap\u0101n\u0101, ASV un ar\u012b da\u017e\u0101s Eiropas valst\u012bs, jau no 1969. gada norit akt\u012bva sadarb\u012bba ar Jap\u0101nas firm\u0101m \u00abTaiho\u00bb un \u00abIskra\u00bb. Ftoraf\u016brs tiek lietots kl\u012bnik\u0101s jau no 1969. gada, medikaments re\u0123istr\u0113ts Latvij\u0101, Polij\u0101, Rum\u0101nij\u0101, Slov\u0101kij\u0101, Ung\u0101rij\u0101, \u010cehij\u0101, \u0136\u012bn\u0101 u.c. Tas ie\u0146em iev\u0113rojamu vietu Grindeka<\/em> kop\u0113j\u0101 p\u0101rdo\u0161anas apjom\u0101 k\u0101 viens no vado\u0161ajiem eksporta prepar\u0101tiem. Ftoraf\u016bra akt\u012bv\u0101 viela tiek eksport\u0113ta uz Jap\u0101nu kop\u0161 1972. gada, bet gatav\u0101 z\u0101\u013cu forma \u2013 400 mg kapsulas \u2013 tiek p\u0101rdotas Jap\u0101nas, k\u0101 ar\u012b vair\u0101ku Eiropas valstu z\u0101\u013cu tirgos.<\/p>\n","protected":false},"excerpt":{"rendered":"